Abstract: The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.

Abstract: The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.

Abstract: The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.

Abstract: Methods are provided using high pressure to treat aggregated interferons, to reduce the aggregate content of interferon material. In particular, recombinant human interferon-? may be so treated. Multiple strategies may be used in combination to make nonglycosylated IFN-? more amenable to high pressure treatment. When coupled with purification techniques, these strategies singly or in combination provide a low aggregate or substantially aggregate free, biologically active solution. In certain aspects, pharmaceutical compositions containing nonglycosylated interferon having less than about 5 weight percent of protein aggregation are provided.

Abstract: The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.

Abstract: High pressure to treat aggregated interferons, particularly recombinant human interferon-?, to reduce the aggregate content of interferon material. Highly pure, soluble monomeric recombinant interferon-? is prepared in representative embodiments. Multiple strategies may be used in combination that make nonglycosylated IFN-? more amenable to high pressure treatment. It has been found that refolding yields of high pressure treatment can be significantly improved by use of a combination of strategies, including, or example a pre-treatment of the IFN-? that involves solubilizing and then precipitating the protein. This pre-treatment is particularly effective with respect to recombinant IFN-? inclusion bodies recovered from host cells such as E. coli cells. According to another strategy, refolding under high pressure is much more effective when the refolding reagent incorporating the IFN-? incorporates a zwitterionic surfactant and/or a cholate salt.

Abstract: The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.

Abstract: Provided herein are a variety of methods and compositions for regulating angiogenesis, such methods and compositions being useful in a variety of applications where modulation of vascular formation is useful, including, but not limited to, treatments for ischemia and wound healing. Certain of the methods and compositions accomplish this by using various zinc finger proteins that bind to particular target sites in one or more VEGF genes. Nucleic acids encoding the zinc finger proteins are also disclosed. Methods for modulating the expression of one or more VEGF genes with the zinc finger proteins and nucleic acids are also disclosed. Such methods can also be utilized in a variety of therapeutic applications that involve the regulation of endothelial cell growth. Pharmaceutical compositions including the zinc finger proteins or nucleic acids encoding them are also provided.

Abstract: The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.

Abstract: The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.

Abstract: The present invention provides methods for altering tumor growth using zinc finger proteins.

Abstract: The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.

Abstract: The invention provides criteria and methods for selecting optimum subsequence(s) from a target gene for targeting by a zinc finger protein. Some of the methods of target site selection seek to identify one or more target segments having a DNA motif containing one or more so-called D-able subsites having the sequence 5?NNGK3?. Other methods of the invention are directed to selection of target segments within target genes using a correspondence regime between different triplets of three bases and the three possible positions of a triplet within a nine-base site. In another aspect, the invention provides methods of designing zinc finger proteins that bind to a preselected target site. These methods can be used following the preselection of target sites according to the procedures and criteria described above. The methods of design use a database containing information about previously characterized zinc finger proteins.

Abstract: Provided herein are a variety of methods and compositions for regulating angiogenesis, such methods and compositions being useful in a variety of applications where modulation of vascular formation is useful, including, but not limited to, treatments for ischemia and wound healing. Certain of the methods and compositions accomplish this by using various zinc finger proteins that bind to particular target sites in one or more VEGF genes. Nucleic acids encoding the zinc finger proteins are also disclosed. Methods for modulating the expression of one or more VEGF genes with the zinc finger proteins and nucleic acids are also disclosed. Such methods can also be utilized in a variety of therapeutic applications that involve the regulation of endothelial cell growth. Pharmaceutical compositions including the zinc finger proteins or nucleic acids encoding them are also provided.

Abstract: Provided herein are a variety of methods and compositions for regulating angiogenesis, such methods and compositions being useful in a variety of applications where modulation of vascular formation is useful, including, but not limited to, treatments for ischemia and wound healing. Certain of the methods and compositions accomplish this by using various zinc finger proteins that bind to particular target sites in one or more VEGF genes. Nucleic acids encoding the zinc finger proteins are also disclosed. Methods for modulating the expression of one or more VEGF genes with the zinc finger proteins and nucleic acids are also disclosed. Such methods can also be utilized in a variety of therapeutic applications that involve the regulation of endothelial cell growth. Pharmaceutical compositions including the zinc finger proteins or nucleic acids encoding them are also provided.

Abstract: High pressure to treat aggregated interferons, particularly recombinant human interferon-?, to reduce the aggregate content of interferon material. Highly pure, soluble monomeric recombinant interferon-? is prepared in representative embodiments. Multiple strategies may be used in combination that make nonglycosylated IFN-? more amenable to high pressure treatment. It has been found that refolding yields of high pressure treatment can be significantly improved by use of a combination of strategies, including, or example a pre-treatment of the IFN-? that involves solubilizing and then precipitating the protein. This pre-treatment is particularly effective with respect to recombinant IFN-? inclusion bodies recovered from host cells such as E. coli cells. According to another strategy, refolding under high pressure is much more effective when the refolding reagent incorporating the IFN-? incorporates a zwitterionic surfactant and/or a cholate salt.

Abstract: Provided herein are a variety of methods and compositions for regulating angiogenesis, such methods and compositions being useful in a variety of applications where modulation of vascular formation is useful, including, but not limited to, treatments for ischemia and wound healing. Certain of the methods and compositions accomplish this by using various zinc finger proteins that bind to particular target sites in one or more VEGF genes. Nucleic acids encoding the zinc finger proteins are also disclosed. Methods for modulating the expression of one or more VEGF genes with the zinc finger proteins and nucleic acids are also disclosed. Such methods can also be utilized in a variety of therapeutic applications that involve the regulation of endothelial cell growth. Pharmaceutical compositions including the zinc finger proteins or nucleic acids encoding them are also provided.

Abstract: The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.

Abstract: Disclosed herein are compositions comprising an engineered zinc finger protein and a nuclear hormone receptor transcriptional control domain, polynucleotides encoding one or more components of the compositions, methods of making the compositions and methods of using these compositions, for example to modulate gene expression and/or to generate transgenic plants or animals.

Abstract: Provided herein are a variety of methods and compositions for regulating angiogenesis, such methods and compositions being useful in a variety of applications where modulation of vascular formation is useful, including, but not limited to, treatments for ischemia and wound healing. Certain of the methods and compositions accomplish this by using various zinc finger proteins that bind to particular target sites in one or more VEGF genes. Nucleic acids encoding the zinc finger proteins are also disclosed. Methods for modulating the expression of one or more VEGF genes with the zinc finger proteins and nucleic acids are also disclosed. Such methods can also be utilized in a variety of therapeutic applications that involve the regulation of endothelial cell growth. Pharmaceutical compositions including the zinc finger proteins or nucleic acids encoding them are also provided.